Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources
Open Access
- 1 November 2019
- journal article
- letter
- Published by Elsevier BV in World Allergy Organization Journal
- Vol. 12 (11), 100079
- https://doi.org/10.1016/j.waojou.2019.100079
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous UrticariaPharmacoEconomics, 2016
- Effect of omalizumab on angioedema in H1‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ACT, a randomized controlled trialAllergy, 2016
- Long-term side effects of glucocorticoidsExpert Opinion on Drug Safety, 2016
- Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous UrticariaAmerican Journal of Clinical Dermatology, 2015
- Biologic agents and the therapy of chronic spontaneous urticariaCurrent Opinion in Allergy and Clinical Immunology, 2014
- Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practiceExpert Opinion on Biological Therapy, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaThe New England Journal of Medicine, 2013
- Rupatadine for the treatment of allergic rhinitis and urticariaExpert Review of Clinical Immunology, 2011
- Challenges in the Management of Chronic UrticariaWorld Allergy Organization Journal, 2011
- How to assess disease activity in patients with chronic urticaria?Allergy, 2008